LAUSR

2 s c Open debate: Dr. Beatriz Lagos (HAL allergy): In the talk given by Dr. Tabar, she has emphasized the importance of the variability among different batches, and its impact in efficacy and safety. Some European companies perform an in-house double validation, which is also sent to the Paul Erlich Institute. What is the relevance that prescriptors give to such procedure? Dr. Ana Tabar: It is quite important, the more variables that are under our control, the best treatments we will have. For instance, in the last four years, our knowledge in mite allergens has drastically increased with more than 30 allergens being described. The mite trials shown during my presentation were published in 2016, and there are another 2 more trials currently in press but not publicly available. If an extract contains a certain allergen, it should be acknowledged, in the same way that we know the amount of Ole e 9 included in certain olive extracts. In other context, it is a similar situation as what happens with the Api m 10, which amount in the extracts should be stated, because it has shown to be crucial in the efficacy of bee venom allergy. If the Immunotherapy companies are aware